| Trial ID: | L5162 |
| Source ID: | NCT00663884
|
| Associated Drug: |
Mitiglinide
|
| Title: |
Glufast On Insulin Glargine Trial in Type 2 DM
|
| Acronym: |
GLORIA
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: Mitiglinide|DRUG: Voglibose
|
| Outcome Measures: |
Primary: Change of HbA1c before and after administration of test drug, 20 weeks | Secondary: Change of self-monitoring of blood glucose before and after administration of test drug, 20 weeks|Change of insulin dose before and after administration of test drug, 20 weeks|Achievement rate of HbA1c target level (rate of the patients whose HbA1c were improved under 6.5% after administration), 20 weeks|Change of CRP, 8-OHdG and Nitrotyrosine before and after administration of test drug, 20 weeks
|
| Sponsor/Collaborators: |
Sponsor: JW Pharmaceutical
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
167
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2008-02
|
| Completion Date: |
2009-09
|
| Results First Posted: |
|
| Last Update Posted: |
2012-03-30
|
| Locations: |
The Catholic Univ. of Korea, Kangnam ST. Mary's Hospital, Seoul, 137-701, Korea, Republic of
|
| URL: |
https://clinicaltrials.gov/show/NCT00663884
|
